FDA’s New JAK Safety Restrictions Spell Trouble for AbbVie’s Rinvoq, but to What Extent?
From: FiercePharma By: Angus Liu A recent survey of 100 high-volume U.S. rheumatologists that Piper Sandler conducted with Spherix Global Insights showed that only 14% of patients are getting Rinvoq as prior to TNF inhibitors. And a large number of physicians are avoiding JAKs for patients with high or moderate blood clot risks. Rinvoq […]
Early Sales of Biogen’s Alzheimer Drug Remain Unclear
From: Barron’s By: Josh Nathan-Kazis In a Wednesday note, Piper Sandler analyst Christopher Raymond cut his estimate for near-term sales, saying that an August survey of neurologists who treat Alzheimer’s disease showed a downward shift in their projections of Aduhelm’s use. The survey, conducted by the market research group Spherix Global Insights, polled 74 neurologists. The […]
J&J’s Ponvory May Be Late to the Multiple Sclerosis Market, but Doctors Still See Potential: Study
From: FiercePharma By: Beth Snyder Bulik Johnson & Johnson’s Ponvory is the fourth in its class and the ninth branded oral drug in multiple sclerosis, and it hasn’t exactly sped out of the starting gate. But it’s off to a surprisingly good start when it comes to physician opinions, a survey found. In a Spherix Global Insights survey, physicians projected a […]
Spherix Global Insights Finds US Gastroenterologists Receptive to Emerging Celiac Disease Pipeline Therapies as More Than One-Third of Patients Struggle to Adhere to Their Gluten-Free Diet
In addition to a thorough evaluation of the current diagnosis and management of celiac disease (CeD), five pipeline product profiles were evaluated by US gastroenterologists to assess strengths, weaknesses, and physician receptivity EXTON, Pa., August 5, 2021 /PRNewswire/ — Spherix recently surveyed 101 US gastroenterologists and conducted eleven qualitative interviews to assess the current and future management […]
Ardelyx Slashes One-Third of its Workforce After FDA Rejection for Key Kidney Disease Prospect
From: FiercePharma By: Fraiser Kansteiner In the aftermath of a surprise FDA rejection in chronic kidney disease, Ardelyx is tightening its belt. Under the restructuring plan, which kicked off Monday and is expected to wrap up this month, the biotech will part ways with 33% of its workforce, or about 83 employees. Ardelyx expects […]
‘Erratic’ FDA and Inconsistent Drug Decisions Put Doctors Off New Meds: Survey
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately—and doctors have had enough. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in […]
Specialty Physicians Weigh in with Opinions About the US Food and Drug Administration
Spherix Global Insights reveals eroding confidence in the FDA as specialists question recent regulatory developments for Biogen’s Aduhelm, Fibrogen/AstraZeneca’s roxadustat, Ardelyx’s tenapanor, and the entire JAK inhibitor class EXTON, Pa., July 27, 2021 /PRNewswire/ — In reaction to major market events over the past several months, analysts at Spherix recently captured an increasingly negative sentiment towards the […]
Switching in Rheumatoid Arthritis: Will JAK Inhibitors Peak or Plummet?
By: Maxine Yarnall There’s a reason why Spherix focuses on the new start and switching patient populations within the indications that we cover: it’s where brands have the opportunity to capture share. Whether a patient is initiated on or switched from one advanced systemic therapy to another, there is a window of opportunity for one […]
Scandal Aside, Biogen’s Aduhelm Sales Set to Reach $1B Next Year and $6B+ by 2025: Analysts
From: FiercePharma By: Noah Higgins-Dunn The analysts based the belief on the latest survey results from Spherix Global Insights, which suggest a very gradual uptake so far. In the first month since its approval, the survey found two neurologists—or 2% of respondents—prescribed the treatment for three patients…(read more)
Cleveland Clinic and Mount Sinai say they will not administer controversial Alzheimer’s drug
From: Daily Mail By: Mansur Shaheen A survey of neurologists by Spherix Global Insights found that neurologists only believe the drug is adequate for use in one-in-seven Alzheimer’s patients…(read more)
